William Martin-Doyle, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Urinary Bladder Neoplasms | 6 | 2015 | 2195 | 0.900 |
Why?
|
| Cystectomy | 4 | 2015 | 603 | 0.530 |
Why?
|
| Electric Countershock | 1 | 2010 | 534 | 0.290 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2015 | 2846 | 0.240 |
Why?
|
| Mediastinal Neoplasms | 2 | 2018 | 403 | 0.240 |
Why?
|
| Neoadjuvant Therapy | 2 | 2014 | 2907 | 0.220 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2010 | 2258 | 0.180 |
Why?
|
| Comprehension | 1 | 2024 | 638 | 0.160 |
Why?
|
| Health Literacy | 1 | 2024 | 466 | 0.160 |
Why?
|
| Catheter Ablation | 2 | 2015 | 2780 | 0.150 |
Why?
|
| Language | 1 | 2024 | 1557 | 0.120 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2018 | 11878 | 0.120 |
Why?
|
| Clinical Trials as Topic | 1 | 2010 | 8052 | 0.120 |
Why?
|
| Dilatation, Pathologic | 1 | 2015 | 527 | 0.110 |
Why?
|
| Ureteral Neoplasms | 1 | 2014 | 107 | 0.100 |
Why?
|
| Colitis | 1 | 2020 | 1242 | 0.100 |
Why?
|
| Lymphoma, B-Cell | 1 | 2018 | 945 | 0.090 |
Why?
|
| Antineoplastic Agents | 1 | 2014 | 13677 | 0.090 |
Why?
|
| Urinary Tract | 1 | 2014 | 305 | 0.090 |
Why?
|
| Hospitalization | 1 | 2010 | 10840 | 0.090 |
Why?
|
| Aortic Valve Insufficiency | 1 | 2015 | 577 | 0.090 |
Why?
|
| Pulmonary Veins | 1 | 2015 | 758 | 0.080 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2014 | 3556 | 0.070 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2017 | 1437 | 0.070 |
Why?
|
| Heart Valve Diseases | 1 | 2015 | 1030 | 0.070 |
Why?
|
| Aorta | 1 | 2015 | 2045 | 0.070 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2015 | 1751 | 0.070 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2013 | 794 | 0.070 |
Why?
|
| Vitamin D | 1 | 2020 | 3311 | 0.070 |
Why?
|
| Etoposide | 2 | 2018 | 639 | 0.070 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2015 | 9419 | 0.070 |
Why?
|
| Vincristine | 2 | 2018 | 1040 | 0.060 |
Why?
|
| Aortic Valve | 1 | 2015 | 1970 | 0.060 |
Why?
|
| Positron-Emission Tomography | 2 | 2018 | 6669 | 0.060 |
Why?
|
| Carcinoma | 1 | 2014 | 2332 | 0.050 |
Why?
|
| Cyclophosphamide | 2 | 2018 | 2227 | 0.050 |
Why?
|
| Models, Biological | 1 | 2018 | 9497 | 0.050 |
Why?
|
| Prostatic Neoplasms | 1 | 2024 | 11101 | 0.050 |
Why?
|
| Melanoma | 1 | 2020 | 5706 | 0.050 |
Why?
|
| Doxorubicin | 2 | 2018 | 2234 | 0.050 |
Why?
|
| Disease-Free Survival | 3 | 2018 | 6847 | 0.040 |
Why?
|
| Prognosis | 3 | 2017 | 30009 | 0.040 |
Why?
|
| Humans | 14 | 2024 | 768171 | 0.040 |
Why?
|
| Cohort Studies | 3 | 2015 | 41753 | 0.040 |
Why?
|
| Cisplatin | 2 | 2014 | 1660 | 0.040 |
Why?
|
| Kidney Neoplasms | 1 | 2014 | 4282 | 0.030 |
Why?
|
| Atrial Fibrillation | 1 | 2015 | 5176 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 2 | 2014 | 3620 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2018 | 20762 | 0.030 |
Why?
|
| Treatment Outcome | 3 | 2017 | 65379 | 0.030 |
Why?
|
| Patient Education as Topic | 1 | 2024 | 2337 | 0.030 |
Why?
|
| Prevalence | 1 | 2010 | 15869 | 0.030 |
Why?
|
| Preoperative Period | 1 | 2015 | 565 | 0.030 |
Why?
|
| Male | 8 | 2024 | 364731 | 0.030 |
Why?
|
| Prednisone | 1 | 2017 | 1567 | 0.030 |
Why?
|
| Lymphocytes | 1 | 2020 | 2614 | 0.020 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2017 | 1791 | 0.020 |
Why?
|
| Survival Rate | 2 | 2018 | 12840 | 0.020 |
Why?
|
| Urothelium | 1 | 2014 | 275 | 0.020 |
Why?
|
| Middle Aged | 7 | 2024 | 223487 | 0.020 |
Why?
|
| Aged | 6 | 2024 | 171502 | 0.020 |
Why?
|
| Mucous Membrane | 1 | 2014 | 659 | 0.020 |
Why?
|
| Physician-Patient Relations | 1 | 2024 | 3269 | 0.020 |
Why?
|
| Carboplatin | 1 | 2014 | 797 | 0.020 |
Why?
|
| Cryosurgery | 1 | 2015 | 479 | 0.020 |
Why?
|
| Communication | 1 | 2024 | 3905 | 0.020 |
Why?
|
| Female | 7 | 2020 | 397187 | 0.020 |
Why?
|
| Predictive Value of Tests | 2 | 2018 | 15453 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2017 | 4861 | 0.020 |
Why?
|
| Carcinoma in Situ | 1 | 2014 | 788 | 0.020 |
Why?
|
| Neutrophils | 1 | 2020 | 3786 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2017 | 6525 | 0.020 |
Why?
|
| Paclitaxel | 1 | 2014 | 1733 | 0.020 |
Why?
|
| Lymphatic Metastasis | 1 | 2013 | 2914 | 0.020 |
Why?
|
| Aged, 80 and over | 2 | 2024 | 59626 | 0.020 |
Why?
|
| Adult | 5 | 2018 | 223646 | 0.010 |
Why?
|
| Reoperation | 1 | 2014 | 4329 | 0.010 |
Why?
|
| Thrombosis | 1 | 2017 | 2957 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 2020 | 9262 | 0.010 |
Why?
|
| Recurrence | 1 | 2015 | 8509 | 0.010 |
Why?
|
| Animals | 1 | 2015 | 169285 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 2017 | 11244 | 0.010 |
Why?
|
| United States | 1 | 2010 | 73039 | 0.010 |
Why?
|
| Age Factors | 1 | 2017 | 18415 | 0.010 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2014 | 4058 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2013 | 10397 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2015 | 24318 | 0.010 |
Why?
|
| Young Adult | 1 | 2017 | 60066 | 0.010 |
Why?
|
| Child | 1 | 2017 | 80917 | 0.010 |
Why?
|
| Adolescent | 1 | 2017 | 89169 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2017 | 81760 | 0.000 |
Why?
|